Company profile for Azafaros

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros' proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no...
Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with diseasemodifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros' proprietary lead compound AZ-3102 will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies today. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
J.H. Oortweg 21 2333 CH Leiden The Netherlands
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251210848919/en/Azafaros-Further-Strengthens-Its-Board-of-Directors-With-Appointment-of-Biotech-Entrepreneur-Dr.-Thierry-Abribat

BUSINESSWIRE
11 Dec 2025

https://www.businesswire.com/news/home/20250727003310/en/Azafaros-Announces-Initiation-of-two-Global-Phase-3-studies-with-Nizubaglustat-in-Niemann-Pick-disease-Type-C-NPC-and-GM1GM2-gangliosidoses-respectively

BUSINESSWIRE
28 Jul 2025

https://www.businesswire.com/news/home/20250608410983/en/Azafaros-to-Present-at-BIO-International-Convention-2025-Following-Successful-%E2%82%AC132M-Series-B-Financing

BUSINESSWIRE
09 Jun 2025

https://endpts.com/dutch-biotech-azafaros-gets-146m-for-phase-3-trials-in-three-metabolic-disorders/

ENDPTS
13 May 2025

https://www.businesswire.com/news/home/20250108672251/en

BUSINESSWIRE
09 Jan 2025

https://www.businesswire.com/news/home/20250107508677/en

BUSINESSWIRE
08 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty